🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseAlcohol + MASH + GLP-1 — can semaglutide help alcohol-related liver disease?

Alcohol + MASH + GLP-1 — can semaglutide help alcohol-related liver disease?

Dr.AddMedPHL Mon, May 25, 2026 at 1:39 PM 16 replies 378 viewsPage 1 of 4
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
May 25, 2026 at 1:39 PM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

The narrow version of the question is what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
42 12FitDadDave, RunnerRach, TrialNerd_Beth and 39 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
May 25, 2026 at 1:56 PM#2
Dr.AddMedPHL said:
Steady state is the thing most people miss.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Last edited: May 25, 2026 at 3:56 PM
41 11PharmD_Rodriguez, julia.endo, JessicaM_2024 and 38 others
Reply Quote Save Share Report
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
May 25, 2026 at 2:13 PM#3
Dr.AddMedPHL said:
Steady state is the thing most people miss.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

40 10DeniseRN_TPA, SandraNC_45, Dr.EndoIndy and 37 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
May 25, 2026 at 2:30 PM#4

Answering the narrow version, because the broad one does not have a single answer. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

39 9RickReta_CO, PharmHunterJen, TomTeleRx and 36 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
May 25, 2026 at 3:58 PM#5
LibrarianMeg said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

38 8TirzTom, TrialTracker_MD, JennaRN and 35 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register